Genenta Science S.p.A. - American Depositary Shares (GNTA)

Sòphia High Tech designs and manufactures ROMAN units for the remote inspection and maintenance of the RFX-mod2 fusion experiment, combining its precision manufacturing capabilities with the robotics expertise of University of Naples Federico II and Herobots, extending the group's precision-engineering capabilities into the nuclear domain

Sales rise 29.3% and EBITDA grows 68.1%; newly appointed Board of Directors to lead the next phase of aerospace and defense growth

Sphere 3D Corp. (NASDAQ: ANY) surged more than 100% in early trading, with over $100 million in shares traded , after announcing the completion of its merger with Cathedra Bitcoin, creating a scaled digital infrastructure platform with 53 megawatts (MW) of operating power capacity and a 100MW+ expansion pipeline targeting AI infrastructure, data centers, high-performance computing (HPC), and digital asset markets .

Genenta enters aerospace as it continues its strategic transformation into a next-generation industrial consolidator

MILAN, March 27, 2026 (GLOBE NEWSWIRE) -- Genenta Science S.p.A. (Nasdaq: GNTA), evolving into Saentra Forge1, a strategic industrial consolidator focused on biotech, defense, aerospace, and Italian national-security-related technologies, today announced that it has entered into a binding offer with Sòphia High Tech S.r.l., (Sòphia HT) an Italian company manufacturing critical parts for Europe's space and defense programs, under which Genenta will fund Sòphia through two reserved capital increases, with the goal of reaching a controlling stake upon the achievement of defined performance milestones. The transaction with Sòphia High Tech would be completed in two phases and remains subject to confirmatory due diligence, required approvals, and definitive transaction documentation.

Focused on selective acquisitions of high-quality companies in strategic industrial sectors

MILAN, March 13, 2026 (GLOBE NEWSWIRE) -- Genenta Science S.p.A. (Nasdaq: GNTA) transforming to Saentra Forge (Nasdaq: SAEN)1, a strategic industrial consolidator focused on biotech, defense, aerospace, and Italian national-security-related technologies, today announced that Pierluigi Paracchi, CEO of the Company, has been appointed as a member of the Board of Guarantors of the Italian Academy for Advanced Studies in America, the prestigious center for advanced scholarship hosted at Columbia University in New York, dedicated to promoting Italian culture, research, and intellectual exchange between Italy and the United States.

Nature Medicine Accepts Manuscript Highlighting Clinical Results from the Company’s Glioblastoma Trial

MILAN and NEW YORK, Jan. 27, 2026 (GLOBE NEWSWIRE) -- In response to evolving market dynamics and strategic opportunities, Genenta Science S.p.A (Nasdaq: GNTA) is embarking on a strategic transformation to evolve into a next-generation strategic industrial consolidator focused on acquiring privately held businesses operating in national-security regulated sectors contemplated by the Italian Golden Power1 legislation. The Company intends to target majority ownership in companies with established operating profitability, typically generating up to approximately €5 million in EBITDA2. In this context, Genenta plans to adopt the new corporate name of Saentra Forge S.p.A. with a new Nasdaq ticker symbol of SAEN3.

MILAN and NEW YORK, Dec. 19, 2025 (GLOBE NEWSWIRE) -- Genenta Science (Nasdaq: GNTA), a clinical-stage gene-therapy company developing hematopoietic stem-cell-based immunotherapies for solid tumors, provides an update regarding the ownership position of its Chief Executive Officer and Co-Founder, Pierluigi Paracchi.

The company said that 25 patients have been treated with Temferon as of November 21, and 44% of glioblastoma multiforme patients have reached 18-month survival.

Company Announces Approximately $30 Million in Cash and Short-Term Investments Following Its October 27th Registered Direct Offering